GE HealthCare (GEHC) is Down 28% and Wall Street is Starting to Buy. Is the Selloff Finally Over?
GE HealthCare (GEHC) fell 28% to $64.81, near its 52-week low, due to China sales stagnation and tariffs. Needham initiated coverage with a Buy rating and $93 target, citing undervaluation. Bulls highlight recurring revenue and AI tools, while bears point to China market share losses and cost uncertainties. The stock's future hinges on China recovery and tariff impacts.
How this was made
The 30-second read
Why it matters
Analyst coverage could reverse the selloff if investors buy on the new target, but execution hinges on upcoming earnings and deal progress.
Market read
The coverage upgrade provides a fresh catalyst for GEHC, potentially influencing the broader healthcare equipment sector.
What to watch
Uncertainty around the Sofie Biosciences acquisition and ongoing tariff refunds.
Background
GE HealthCare has been pressured by China market weakness, tariffs, and hospital capital spending constraints, leading to a 28% decline.
Ticker impact
Needham initiated coverage with a Buy rating and a $93 price target, citing valuation upside after a 28% price drop.
Potential upside of ~44% if target is reached.
Coverage initiation is a fresh catalyst; the sizable price target suggests a notable upside, but execution depends on broader market sentiment and upcoming earnings.
Market effects
May lift other medical imaging and diagnostic equipment stocks as investors reassess valuations.
Potential positive effect on US healthcare sector indices.
Limited to US-listed healthcare equipment space.
Counterpoint
The China sales slowdown and tariff hit could outweigh valuation benefits, keeping downside risk.
Key entities
- CompanyGE HealthCare Technologies Inc.
US-listed medical imaging and contrast agent provider (NASDAQ:GEHC).
- Research FirmNeedham
Initiated coverage with a Buy rating and $93 price target.
